Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in North Carolina

You’re a psychiatrist managing a patient on an antipsychotic who’s gained 40 pounds in six months. Or maybe you’re a PMHNP considering adding weight management to your practice because half your patients ask about it. The question comes up constantly: Can I legally prescribe GLP-1s or other weight-loss meds via telehealth?

The short answer: Yes, if you navigate the rules correctly. But those rules change dramatically by state, provider type, and whether you’re prescribing controlled substances.

Let’s cut through the confusion with what actually matters for your practice.

The Current Federal Landscape: DEA Rules and the 2026 Extension

Here’s where many providers get tripped up. Under the Ryan Haight Act (2008), prescribing controlled substances via telemedicine normally requires an in-person exam first. During COVID, the DEA waived this requirement.

Current status as of 2026: The DEA and HHS extended the telehealth flexibilities through December 31, 2026. This means you can continue prescribing controlled substances (including Schedule IV weight-loss drugs like phentermine) via telehealth to new patients without an initial in-person visit — but only until the end of 2026.

What happens after? The DEA is developing permanent rules that will likely require a ‘Special Telemedicine Registration’ or impose limits like initial 30-day supplies for remote prescribing. The exact requirements aren’t finalized, but expect more restrictions than we have today.

The critical distinction for weight loss: Most modern obesity medications (semaglutide/Wegovy, tirzepatide/Zepbound) are not controlled substances. You can prescribe these via telehealth in most states with standard prescribing protocols — no DEA restrictions apply. It’s the older appetite suppressants like phentermine that fall under controlled substance rules.

For psychiatrists, this matters because you might prescribe GLP-1s off-label to manage antipsychotic-induced weight gain — perfectly legal from a federal standpoint. But phentermine? That’s where state rules get complicated.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Can Psychiatrists Prescribe Weight-Loss Medications? Scope of Practice Reality

As a physician (MD/DO), yes — you have broad prescribing authority. There’s no ‘obesity medicine license’ required. If you’re competent to manage the treatment and follow standard of care, you can prescribe weight-loss medications even though it’s not your specialty.

The question is less about can you and more about should you and how to do it right.

What ‘Competent to Treat’ Actually Means

State medical boards hold you to the same standard as any physician treating obesity. In Florida, for example, you must:

• Document the patient’s BMI (≥30 or ≥27 with comorbidities)
• Conduct a proper initial evaluation (history, physical exam, relevant labs)
• Obtain written informed consent about medication risks
• Re-evaluate the patient at least every 3 months

These aren’t suggestions — they’re regulatory requirements that apply to any physician prescribing weight-loss drugs in Florida, psychiatrist or not.

The practical challenge: Psychiatrists typically focus on mental status exams, not metabolic parameters. If you’re prescribing semaglutide, you need to monitor for GI side effects, check for contraindications (personal/family history of medullary thyroid cancer), discuss injection technique, and coordinate with the patient’s primary care for baseline labs (kidney function, lipid panel).

Many psychiatrists handle this by incorporating weight management as an adjunct to psychiatric care — for example, prescribing a GLP-1 to offset olanzapine-induced weight gain while managing the patient’s bipolar disorder. That’s a legitimate integrated approach. But running a standalone telehealth weight-loss service? That’s further from your usual scope and carries more risk if you’re not prepared to provide comprehensive obesity care.

PMHNPs and Scope-of-Practice Risk

For Psychiatric-Mental Health Nurse Practitioners, the scope question is more restrictive. Your certification is in mental health — treating obesity could be viewed by state nursing boards as outside your training.

In states like Texas and Florida, scope is tied to ‘what a reasonably prudent practitioner with similar training would do.’ A PMHNP treating weight loss would likely need:

• A collaborating physician (ideally in family medicine or endocrinology, not just another psychiatrist)
• An explicit protocol covering weight-loss treatment in the collaborative agreement
• Additional training or certification in obesity medicine to demonstrate competence

Some states offer more flexibility. California’s AB 890 allows experienced NPs to practice independently starting in 2026 if they meet certain criteria — but that independence is still within their population focus. An independently practicing PMHNP might face scrutiny if most of their practice shifts to weight management rather than mental health.

Bottom line for PMHNPs: Tread carefully. You can prescribe weight-loss meds in many states under appropriate physician collaboration, but you’re assuming liability if something goes wrong and a board reviews whether you were practicing within your scope.

State-by-State Rules: Where the Real Complexity Lives

Federal rules set the floor, but states can be much stricter. Here’s what matters in key markets:

New York: The In-Person Exam Wall

New York is the most restrictive state for controlled substances. As of 2025, you must conduct at least one in-person medical evaluation before prescribing any controlled substance to a new patient.

The exceptions are narrow:

• Another NY provider examined the patient in person within the last 12 months and referred them to you
• You’re covering for a colleague who established the patient relationship
• Emergency situation with an existing patient (5-day supply max)

What this means practically: If you’re a New York psychiatrist wanting to prescribe phentermine via telehealth to a new patient, you need to either see them in person first or partner with a local clinic that can do the initial exam.

For non-controlled weight-loss medications (GLP-1s), New York has no such restriction. You can prescribe via telehealth as long as you conduct an appropriate evaluation — video is recommended, though NY does allow audio-only for mental health services in certain circumstances.

New York also requires checking the state’s Prescription Monitoring Program (PMP) within 24 hours before prescribing any Schedule II-IV controlled substance, and all prescriptions must be sent electronically (EPCS for controlled substances).

Florida: Schedule II Ban, But Psych Gets an Exception

Florida prohibits prescribing Schedule II controlled substances via telehealth except for specific scenarios — and psychiatric treatment is one of them.

This creates an interesting split: Florida psychiatrists can prescribe Adderall or other Schedule II ADHD meds via telemedicine (because it’s treating a psychiatric disorder), but they cannot prescribe Schedule II stimulants for weight loss via telehealth (obesity isn’t a psychiatric condition).

For Schedule IV drugs like phentermine, Florida’s telehealth law doesn’t restrict them — you can prescribe via telemedicine to treat obesity.

But Florida has aggressive obesity prescribing regulations:

• Patient must meet BMI criteria (≥30 or ≥27 with comorbidities)
• You must obtain written informed consent
• You must re-evaluate every 3 months minimum
• You must provide patients with Florida’s ‘Weight-Loss Consumer Bill of Rights’

Florida also mandates checking the E-FORCSE PDMP before prescribing any controlled substance to patients 16+ years old. These aren’t suggestions — they’re enforceable rules, and Florida has a history of cracking down on ‘pill mills.’

For PMHNPs in Florida: You need a supervising physician to prescribe. Florida has begun allowing autonomous practice for certain experienced APRNs (like Family NPs), but psychiatric NPs still require physician oversight as of 2025. If you want to offer weight-loss treatment, your collaborating physician should ideally have expertise in obesity medicine, not just psychiatry.

California: Flexibility with CPOM Constraints

California is relatively telehealth-friendly. An in-person exam isn’t required if you can conduct an adequate evaluation via video that meets standard of care.

Key requirements:

• Documented telehealth consent (required by state law)
• CURES PDMP check before first fill of any Schedule II-IV medication and every 4 months for ongoing therapy
• Electronic prescribing for all medications (including controlled substances)

California’s unique challenge is the Corporate Practice of Medicine doctrine. Medical services must be provided by physician-owned professional corporations. If you’re joining a telehealth platform or starting a weight-loss service, the business structure matters — non-physicians can’t independently run the clinical operation.

For NPs, California is implementing phased independent practice under AB 890. By 2026, experienced NPs who meet requirements can practice independently within their certified population focus. But again, a PMHNP’s focus is mental health — branching into weight management might require additional justification.

Texas: Delegation Requirements for NPs

Texas allows telehealth prescribing of controlled substances (no state-level in-person requirement), but has strict delegation rules for advanced practice providers.

For NPs and PAs: You must have a Prescriptive Authority Agreement with a Texas-licensed physician that specifically authorizes prescribing weight-loss medications. The delegating physician needs to be available for consultation and review a percentage of your charts.

Texas requires checking the state’s Prescription Monitoring Program (Tx PMP AWARxE) before prescribing controlled substances, and you must provide follow-up care instructions to patients. If the patient consents, you’re required to send a report to their primary care provider within 72 hours of a telehealth encounter.

Corporate practice restrictions apply in Texas too — the weight-loss service needs to be physician-owned or structured properly through a management services organization.

Pennsylvania and Illinois: More Flexibility

Pennsylvania defers largely to federal law for telehealth prescribing. There’s no state ban on controlled substances via telemedicine, though you must check the PA PDMP before prescribing opioids or benzodiazepines (and it’s best practice for any controlled substance).

NPs in Pennsylvania need a collaborative agreement with a physician to prescribe — there’s no independent practice. But the agreements can be flexible, allowing NPs to manage weight loss if the collaborating physician delegates that authority.

Illinois has Full Practice Authority for experienced APRNs (after 4,000 clinical hours and additional training). An Illinois NP with FPA can prescribe all medications including controlled substances independently — though treating obesity as a psychiatric NP would still raise scope questions.

Illinois requires e-prescribing for all controlled substances and checking the state PMP for Schedule II narcotics, but otherwise is telehealth-friendly with no in-person mandate.

The Economics: Why Telehealth Platforms Beat DIY Marketing

Here’s a reality check on patient acquisition that few people talk about honestly.

Many providers think they’ll save money by handling their own marketing — set up a website, run some Google Ads, maybe get listed on Psychology Today. The math rarely works out the way they expect.

Realistic costs of DIY patient acquisition for psychiatric/weight-loss patients:

SEO/Content Marketing:

• 6-12 months before you see meaningful patient flow
• $2,000-4,000/month for a quality agency or consultant
• That’s $12,000-48,000 in upfront investment before your first patient books
• Most solo practitioners don’t have the expertise or patience for this

Google Ads:

• Mental health and weight-loss keywords cost $15-40+ per click
• Conversion rates are terrible — maybe 2-5% of clicks become booked patients
• Realistic cost per booked patient: $200-400+
• And that’s before accounting for no-shows from cold leads

Directory Listings:

• Psychology Today, Zocdoc, etc. charge monthly fees ($30-200/month depending on features)
• You’re competing with hundreds of other providers on the same page
• Zocdoc charges per booking on top of subscription fees
• When you factor in all costs including the value of your time handling leads, total cost per acquired patient often exceeds $300-500

All-in reality: Acquiring a qualified psychiatric or weight-loss patient through DIY marketing typically costs $200-500+ when you account for agency fees, ad spend, testing and optimization time, staff costs to qualify leads, no-show rates, and months of investment before results.

Why Platform Economics Make Sense

Compare that to platforms like Klarity Health that use a pay-per-appointment model:

The actual value proposition:

• No upfront marketing spend or monthly subscription fees
• You only pay when a qualified patient actually books and shows up
• Pre-matched patients already interested in your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule and only pay when you see patients

This is the honest economic case: Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee per new patient lead. That’s guaranteed ROI versus hoping your ad campaign eventually converts.

DIY marketing can eventually be cost-effective if you have the budget, expertise, and patience to build it. But for most providers — especially those starting out or scaling quickly — a platform that handles patient acquisition removes the risk entirely.

Practical Compliance Checklist: Staying Legal Across States

Regardless of where you practice, follow these universal best practices:

1. Verify patient location at every visitState licensure follows the patient, not you. You need to be licensed where they’re physically located during the telemedicine visit. Use a documented process to confirm this.

2. Obtain and document telehealth consentMany states (California, Illinois, and others) require specific consent for telehealth services. Document the consent conversation in your note, covering:

• How telehealth works
• Privacy/security measures
• Limitations (can’t do physical exam, etc.)
• Patient’s agreement to proceed

3. Conduct and document a thorough evaluationState boards review telehealth charts to see if you met standard of care. Your documentation should include:

• Relevant medical history (prior weight-loss attempts, medical conditions, medications)
• For weight loss: Current weight, BMI calculation, comorbidities
• Mental health screening (especially important before prescribing stimulants)
• Assessment of contraindications
• Diet/exercise counseling provided
• Informed consent about medication risks

4. Follow state-specific prescribing protocols

• Florida: Written informed consent, quarterly follow-ups, Consumer Bill of Rights
• New York: In-person exam for controlled substances (or qualified exception)
• All states with PDMPs: Check before prescribing controlled substances and document it

5. Use PDMPs and e-prescribing diligentlyThis isn’t just a legal requirement in most states — it’s critical patient safety. Check for:

• Other controlled substances the patient is taking
• Doctor shopping behavior
• Contraindicated combinations

Most states now require electronic prescribing for controlled substances (EPCS).

6. Coordinate with primary careMany state regulations (like Texas) require or encourage you to communicate with the patient’s primary care provider when treating via telehealth. Even where it’s not required, it’s good practice — especially for something like weight management that involves metabolic monitoring.

Document that you:

• Asked for the patient’s PCP information
• Offered to send a treatment summary (with patient consent)
• Advised the patient to follow up with PCP for labs or other monitoring

FAQ: Common Questions Providers Actually Ask

Can I prescribe Ozempic for weight loss via telehealth to a new patient?

In most states, yes — semaglutide isn’t a controlled substance, so federal DEA rules don’t apply. You need to:

• Be licensed in the patient’s state
• Conduct an appropriate evaluation via video
• Follow that state’s telehealth standard of care
• Document medical necessity (BMI criteria, etc.)

Exception: New York and a few other states require an in-person exam for any new prescription in some circumstances, but that’s rare for non-controlled meds.

Do I need an in-person visit to prescribe phentermine online?

Depends on the state:

• New York: Yes, you need at least one in-person exam before prescribing any controlled substance (with narrow exceptions)
• Texas, Florida, California, Pennsylvania, Illinois: Currently no, under the federal DEA extension through 2026 — but follow state telehealth standards
• After 2026: Likely yes in most states, or you’ll need special DEA telemedicine registration

As a PMHNP, can I offer weight-loss treatment?

Legally, it depends on your state’s scope rules and whether you have appropriate physician collaboration. Practically, you should ask:

• Does your collaborative agreement specifically authorize weight management?
• Is your collaborating physician comfortable overseeing this (and do they have expertise in obesity medicine)?
• Have you obtained any additional training/certification in weight management?
• How will your state nursing board view this if a patient complaint arises?

If you’re primarily treating mental health and occasionally prescribe a GLP-1 for antipsychotic-related weight gain (coordinating with the patient’s PCP), that’s probably fine. Running a standalone weight-loss telehealth practice as a PMHNP? Riskier without additional safeguards.

What’s the difference between prescribing GLP-1s for diabetes versus weight loss?

From a regulatory standpoint, not much — both are valid medical indications when appropriate. The prescribing standard of care is the same.

The reimbursement difference is huge: Many insurance plans cover GLP-1s for diabetes but not for weight loss. Some states (like California’s Medi-Cal) are explicitly dropping coverage for weight-loss indications as of 2026, framing it as ‘non-covered.’

If you’re billing insurance, you need a diagnosis code that justifies the prescription. ‘Obesity’ (E66.x codes) might not be covered; ‘Type 2 diabetes’ (E11.x) usually is if the patient actually has diabetes.

Can I prescribe weight-loss meds to patients in multiple states?

Yes, if you’re licensed in each state and comply with that state’s telehealth and prescribing rules. This is where multistate compacts (Interstate Medical Licensure Compact for physicians, Nurse Licensure Compact for nurses) help streamline the process.

Be aware: Prescribing controlled substances across state lines requires DEA registration in the state where you’re practicing and where the patient is located (for controlled substances). Some states have additional rules about out-of-state prescribers.

What happens if the DEA rules change after 2026?

The DEA has indicated they’re working on permanent regulations. Likely outcomes:

• Special telemedicine registration requirement (like the X-waiver was for buprenorphine)
• Possible in-person exam requirement returns for some or all controlled substances
• Limits on initial supplies (e.g., 30-day max for first tele-prescription)

Stay informed by monitoring DEA announcements and professional association guidance (APA, AANP, etc.). Most telehealth platforms will also communicate required changes to their provider network.

Making the Business Case: Should Psychiatrists Add Weight Management?

Let’s be practical about the opportunity and the risks.

Why it makes sense:

• Patient demand is real. At least half of psychiatric patients struggle with weight — either from medications or underlying conditions
• Revenue potential. Weight management visits can be cash-pay (many GLP-1 prescriptions aren’t covered), creating a parallel revenue stream outside insurance hassles
• Clinical synergy. Addressing weight gain from antipsychotics or treating co-occurring binge eating disorder/depression fits naturally with psychiatric care
• Differentiation. Offering integrated mental health + weight management sets you apart from prescribers who ignore metabolic side effects

Why caution is warranted:

• Scope creep liability. If you’re not prepared to provide comprehensive obesity care (nutrition counseling, labs, monitoring), you’re exposed if something goes wrong
• Regulatory scrutiny. Weight-loss prescribing via telehealth is under intense oversight — boards are watching for inappropriate prescribing or ‘pill mill’ patterns
• Time investment. Weight management requires follow-ups, patient education, addressing side effects — it’s not just ‘write a prescription and done’
• Competition. You’re entering a crowded space with established bariatric specialists, endocrinologists, and telehealth startups

The smart middle path: Incorporate weight management as a natural extension of psychiatric care rather than running a separate weight-loss business. For example:

• Prescribe GLP-1s to offset antipsychotic-induced weight gain in your existing patients
• Coordinate with patients’ PCPs rather than trying to manage all metabolic parameters yourself
• Consider additional training or certification in obesity medicine to bolster your credentials
• Partner with a platform that handles patient acquisition and provides clinical support protocols

This approach lets you meet a real patient need, create additional revenue, and stay within a defensible scope — without the risk of looking like you’re just chasing the GLP-1 trend.

Next Steps: Building a Compliant Telehealth Weight-Loss Practice

If you’re serious about adding weight management to your telehealth practice:

1. Get your licensure in order

• Obtain licenses in your target states (consider IMLC if you’re a physician)
• Verify your DEA registrations cover the states where you’ll prescribe controlled substances
• If you’re an NP or PA, ensure your collaborative agreements explicitly cover weight management

2. Build robust clinical protocols

• Intake forms that document BMI, weight-loss history, comorbidities
• Informed consent templates specific to each medication class
• Follow-up schedules that meet or exceed state requirements (e.g., quarterly for Florida)
• PDMP checking workflow integrated into your prescribing process
• Coordination procedures with patients’ primary care providers

3. Choose your platform strategyEither join an established telehealth platform that handles patient acquisition, credentialing, and compliance infrastructure — or build your own marketing and infrastructure.

If you go the DIY route, budget realistically: You’re looking at $3,000-5,000/month in marketing spend plus 6-12 months before meaningful patient flow. Most providers starting out find platforms offer better ROI.

4. Stay current on regulationsSubscribe to updates from:

• DEA announcements on telemedicine prescribing
• Your state medical board or nursing board newsletters
• Professional associations (APA, AANP, etc.)
• Legal resources like the Center for Connected Health Policy (CCHP)

Regulations are evolving quickly — what’s legal today might change by 2027 when the current DEA extension expires.

The Bottom Line

Psychiatrists and PMHNPs can legally prescribe weight-loss medications via telehealth in most states — but the devil is in the details.

For non-controlled medications like GLP-1s, the path is relatively clear: follow standard telehealth protocols and prescribing guidelines. For controlled substances like phentermine, you need to navigate both federal DEA rules (currently flexible through 2026) and state-specific requirements that range from permissive (Texas, California) to highly restrictive (New York).

The biggest risk isn’t legal prohibition — it’s practicing outside your competence or documentation. State boards discipline providers who can’t justify their prescribing decisions or who don’t follow the standard of care for obesity treatment.

If you’re going to do this, do it right: Get the training, build the protocols, document thoroughly, and coordinate with other providers. The patients need this care, and there’s a legitimate business opportunity — but cutting corners in telehealth weight management is asking for trouble.

Ready to add patients who need comprehensive psychiatric and weight management care without the marketing headache? Explore joining Klarity Health’s provider network — we match pre-qualified patients to providers, handle the telehealth infrastructure, and only charge per appointment. No upfront spend, no wasted ad dollars, just patients ready to see you.

References and Sources

1. U.S. Department of Health & Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act). Effective 2019 (accessed November 2025). http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity. Effective August 8, 2022. https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Procter LLP. ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Client Alert, March 30, 2024. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery LLP. ‘Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers.’ Of Digital Interest Blog, September 29, 2023. https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting. ‘California Weight Loss Clinic & Telehealth Compliance Guide (2025).’ 2025. https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting. ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025).’ 2025. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York State Department of Health. 10 NYCRR §80.63 – Prescribing of Controlled Substances. Amended May 2025. https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. Landi, Heather. ‘Primary care doctors concerned about telehealth GLP-1 boom: survey.’ Fierce Healthcare, February 13, 2025. https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

10. California Medical Association. ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal.’ CMA News, December 2, 2025. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

11. Center for Connected Health Policy. ‘State Telehealth Policies for Online Prescribing.’ Updated November 21, 2025. https://www.cchpca.org/topic/online-prescribing/

12. Pennsylvania Department of Health. ‘Prescription Drug Monitoring Program (PDMP) – Prescriber FAQs.’ 2022 (accessed 2025). https://www.pa.gov/agencies/health/programs/opioids/prescribers-and-providers/prescribing-guidelines.html

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated